One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE)A Phase 3 Randomized Clinical Trial
Alexander V. Louie, MD, PhD; Patrick V. Granton, PhD; Alysa Fairchild, MD; et al.
doi : 10.1001/jamaoncol.2021.7664
April 2022, Vol 8, No. 4, Pages 1-651
Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of CancerA Systematic Review and Meta-analysis
Doni Bloomfield, JD; Elvira D’Andrea, MD, MPH; Sarosh Nagar; et al.
Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate CancerThe VIABLE Phase 3 Randomized Clinical Trial
Nicholas J. Vogelzang, MD; Tomasz M. Beer, MD; Winald Gerritsen, MD; et al.
Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction ChemotherapyA Phase 3 Randomized Clinical Trial
Guo-Ying Liu, MD; Wang-Zhong Li, MD; De-Shen Wang, MD; et al.
Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced CancerA Randomized Clinical Trial
Ryan D. Nipp, MD, MPH; Nora K. Horick, MS; Carolyn L. Qian, BA; et al.
Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood DeprivationA Post Hoc Analysis of a Randomized Clinical Trial
Gelareh Sadigh, MD; Robert J. Gray, PhD; Joseph A. Sparano, MD; et al.
Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic VariantsA Comparative Modeling Analysis
Kathryn P. Lowry, MD; H. Amarens Geuzinge, MSc; Natasha K. Stout, PhD; et al.
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
Wei Fang Dai, MPH; Jaclyn M. Beca, MSc; Chenthila Nagamuthu, MPH; et al.
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
Aileen I. Fernandez, PhD; Matthew Liu; Andrew Bellizzi, MD; et al.
SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents
Charlotte Fenioux, MD; Luis Teixeira, MD, PhD; Slim Fourati, MD; et al.
Development of an Open Database of Genes Included in Hereditary Cancer Genetic Testing Panels Available From Major Sources in the US
Janis Geary, PhD; Mary Majumder, JD, PhD; Christi Guerrini, JD, MPH; et al.
Association of Human Papillomavirus Vaccination With the Incidence of Squamous Cell Carcinomas of the Anus in the US
Abbey B. Berenson, MD, PhD; Fangjian Guo, MD, PhD; Mihyun Chang, PhD
Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease
Nour Kibbi, MD; Joshua L. Owen, MD, PhD; Brandon Worley, MD, MSc; et al.
Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast CancerA Review
Paolo Tarantino, MD; Giuseppe Curigliano, MD, PhD; Heather A. Parsons, MD, MPH; et al.
Reexamination of Patient Autonomy and Prior Therapies in Oncology Clinical Trial Eligibility Criteria
Jennifer J. Gao, MD; Richard Pazdur, MD; Julia A. Beaver, MD
Achieving Equity in Lung Cancer Screening for Black Individuals Requires Innovation to Move Beyond “Equal� Guidelines
Hilary A. Robbins, PhD; Rebecca Landy, PhD; Jasjit S. Ahluwalia, MD
Cancer Biosimilars—A Regulatory Success So Far, but Value Still to Be Determined
Douglas W. Blayney, MD; Samuel M. Silver, MD, PhD, MACP
Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer
Hiten D. Patel, MD, MPH; Stephanie Berg, DO
Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma—Magic Bullet or Pandora’s Box?
Wai-Tong Ng, MD; Melvin L. K. Chua, MBBS, PhD; Anne W. M. Lee, MD
Tumor Coverage vs Healthy Tissue Sparing—What Is the Balance When Palliation Is the Goal?
Ashley A. Weiner, MD, PhD; Joel E. Tepper, MD
ERBB2-Low Breast Cancer—Is It a Fact or Fiction, and Do We Have the Right Assay?
Kimberly H. Allison, MD; Antonio C. Wolff, MD
Patient Harassment of Medical TraineesReflections for a More Inclusive Future
Nina D. Arhin, MD; Caroline A. Nebhan, MD, PhD; Walter K. Clair, MD, MPH
Overcoming Our Red Dots and Confronting Racism From Patients
Udit Singhal, MD
Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer—Reply
Scott Gettinger, MD; Mary W. Redman, PhD; Roy S. Herbst, MD, PhD
PSMA PET in Prostate Cancer—A Biomarker or a Surrogate End Point?
Gartrell C. Bowling, BS; Jordan D. Dimitrakoff, MD, PhD
PSMA PET in Prostate Cancer—A Biomarker or a Surrogate End Point?—Reply
Thomas A. Hope, MD; Jeremie Calais, MD
Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer
Xiaomei Huang, MD; Zaiyi Liu, MD
Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer—Reply
Rita Mukhtar, MD; W. Fraser Symmans, MD; Laura J. Esserman, MD, MBA
Interpretation of the Efficacy of Multidisciplinary Geriatric Assessment Intervention on Chemotherapy-Related Toxic Effects in Older Adults With Cancer
Ayumu Matsuoka, MD, PhD; Maiko Fujimori, PhD
Interpretation of the Efficacy of Multidisciplinary Geriatric Assessment Intervention on Chemotherapy-Related Toxic Effects in Older Adults With Cancer
Daisuke Shimizu; Masahiro Takahashi, MD, PhD; Tomonori Mizutani, MD, PhD
Interpretation of the Efficacy of Multidisciplinary Geriatric Assessment Intervention on Chemotherapy-Related Toxic Effects in Older Adults With Cancer—Reply
Daneng Li, MD; Mina S. Sedrak, MD, MS; William Dale, MD, PhD
Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer
Binghao Zhao, MD, PhD; Wenbin Ma, MD
Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer
Manuel David Gil-Sierra, PharmD; MarÃa del Pilar Briceño-Casado, PharmD; Marina Sánchez-Hidalgo, PharmD
